{"nctId":"NCT03211247","briefTitle":"Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age","startDateStruct":{"date":"2017-07-31","type":"ACTUAL"},"conditions":["Peanut Allergy"],"count":414,"armGroups":[{"label":"Part A Viaskin Peanut 250 mcg","type":"EXPERIMENTAL","interventionNames":["Biological: Part A Viaskin Peanut 250 mcg"]},{"label":"Part A Viaskin Peanut 100 mcg","type":"EXPERIMENTAL","interventionNames":["Biological: Part A Viaskin Peanut 100 mcg"]},{"label":"Part A Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Part A Placebo"]},{"label":"Part B Viaskin Peanut 250 mcg","type":"EXPERIMENTAL","interventionNames":["Biological: Part B Viaskin Peanut 250 mcg"]},{"label":"Part B Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Part B Placebo"]}],"interventions":[{"name":"Part A Viaskin Peanut 250 mcg","otherNames":[]},{"name":"Part A Viaskin Peanut 100 mcg","otherNames":[]},{"name":"Part A Placebo","otherNames":[]},{"name":"Part B Viaskin Peanut 250 mcg","otherNames":[]},{"name":"Part B Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female from 1-3 years of age;\n* Physician-diagnosed peanut allergy;\n* Peanut-specific IgE level \\> 0.7 kU/L;\n* Positive peanut SPT with a largest wheal diameter ≥ 6 mm;\n* Positive DBPCFC at ≤ 300 mg peanut protein;\n\nKey Exclusion Criteria:\n\n* Uncontrolled asthma;\n* History of severe anaphylaxis to peanut;\n* Prior immunotherapy to any food or other immunotherapy;\n* Generalized severe dermatologic disease;","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"3 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Treatment Responders at Month 12","description":"A participant was defined as a treatment responder if the initial eliciting dose (ED) was \\> 10 milligram (mg) peanut protein and the ED was ≥1000 mg peanut protein at the post-treatment double-blind placebo-controlled food challenge (DBPCFC) at Month 12 OR the initial ED at baseline was ≤10 mg peanut protein and the ED was ≥300 mg peanut protein at the post-treatment DBPCFC at Month 12.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":null},{"groupId":"OG001","value":"33.5","spread":null},{"groupId":"OG002","value":"52.4","spread":null},{"groupId":"OG003","value":"70.0","spread":null},{"groupId":"OG004","value":"60.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Cumulative Reactive Dose (CRD) of Peanut Protein at Month 12 Using Analysis of Covariance (ANCOVA) Model","description":"The peanut protein CRD was defined as the sum of all peanut protein doses taken by the participant during the DBPCFC, calculated as follows:\n\nIf the ED reported by the investigator in the electronic case report form (eCRF) is missing, then the CRD is missing; If the ED reported by the investigator in the eCRF was not missing then the CRD was calculated as the sum of all doses given, including also the partial doses. The CRD in each treatment group at Month 12 was compared using ANCOVA model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1010.31","spread":null},{"groupId":"OG001","value":"322.57","spread":null},{"groupId":"OG002","value":"788.74","spread":null},{"groupId":"OG003","value":"1155.90","spread":null},{"groupId":"OG004","value":"1153.47","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CRD of Peanut Protein to Month 12","description":"The peanut protein CRD was defined as the sum of all peanut protein doses taken by the participant during the DBPCFC, calculated as follows:\n\nIf the ED reported by the investigator in the eCRF is missing, then the CRD is missing; If the ED reported by the investigator in the eCRF was not missing then the CRD was calculated as the sum of all doses given, including also the partial doses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1300.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"540.0","spread":null},{"groupId":"OG003","value":"1250.0","spread":null},{"groupId":"OG004","value":"1000.0","spread":null}]}]}]},{"type":"SECONDARY","title":"ED of Peanut Protein at Month 12 Using ANCOVA Model","description":"The peanut protein ED was the individual dose of peanut protein administered to participants during the food challenge procedure, which triggered objective allergic reactions, leading to stopping the challenge. The ED in each treatment group at Month 12 was compared using ANCOVA model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"659.36","spread":null},{"groupId":"OG001","value":"223.12","spread":null},{"groupId":"OG002","value":"526.31","spread":null},{"groupId":"OG003","value":"730.38","spread":null},{"groupId":"OG004","value":"760.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in ED of Peanut Protein to Month 12","description":"The peanut protein ED was the individual dose of peanut protein administered to participants during the food challenge procedure, which triggered objective allergic reactions, leading to stopping the challenge.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"900.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"700.0","spread":null},{"groupId":"OG003","value":"700.0","spread":null},{"groupId":"OG004","value":"700.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Severity of Objective Symptoms at Baseline and Month 12 During Double-Blind Placebo-Controlled Food Challenge","description":"The objective symptoms collected during the DBPCFC included skin (erythematous rash, pruritus, urticaria/angioedema, rash), upper respiratory (sneezing/itching, nasal congestion, rhinorrhea, laryngeal), lower respiratory (wheezing), gastrointestinal (diarrhea, vomiting, cardiovascular), and eyes (conjunctivitis, any other objective symptoms), with the exception of erythematous rash (recorded as Yes/No), each symptom was graded as: 0=\" absent\",1=\" mild\", 2=\" moderate\" or 3=\" severe\". For erythematous rash, the percent area involved was collected. Percentages were calculated based on the number of participants in each time point. Subjective abdominal pain (when graded 2 or 3) was also considered for this analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":null},{"groupId":"OG001","value":"7.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"67.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"24.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":null},{"groupId":"OG001","value":"6.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"14.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"51.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":244},"commonTop":["Application Site Erythema","Application Site Pruritus","Application Site Swelling","Upper Respiratory Tract Infection","Pyrexia"]}}}